Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Martin Reck , Tony Mok , Makoto Nishio , Robert Jotte , Federico Cappuzzo , Francisco Orlandi , Daniil Stroyakovskiy (1) , Naoyuki Nogami , Delvys Rodríguez-Abreu , Denis Moro-Sibilot (2) , Christian Thomas (3) , Fabrice Barlesi (4, 5) , Gene Finley , Anthony Lee (6) , Shelley Coleman , Yu Deng (7) , Marcin Kowanetz , Geetha Shankar , Wei Lin (8) , Mark Socinski , Tony Sk Mok

1 Moscow City Oncology Hospital
2 INSERM U823 - Institut d'oncologie/développement Albert Bonniot de Grenoble
3 School of Mathematics and Statistics [Crawley, Perth]
4 APHM - Assistance Publique - Hôpitaux de Marseille
5 CRCM - Centre de Recherche en Cancérologie de Marseille
6 Department of Statistics [Oxford]
7 Wuhan University [China]
8 IGG - Institute of Geology and Geophysics [Beijing]

The IMpower150 trial showed significant improvements in progression-free and overall survival with atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) versus the standard-of-care bevacizumab plus carboplatin plus paclitaxel (BCP) in chemotherapy-naive patients with non-squamous non-small-cell lung cancer. Here, we report the efficacy of ABCP or atezolizumab plus carboplatin plus paclitaxel (ACP) versus BCP in key patient subgroups.

F. Hoffmann-La Roche, Genentech.

Domaines: Sciences du Vivant [q-bio]; Biologie cellulaire

Martin Reck, Tony Mok, Makoto Nishio, Robert Jotte, Federico Cappuzzo, et al.. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. The Lancet Respiratory Medicine, 2019, 7 (5), pp.387-401. ⟨10.1016/S2213-2600(19)30084-0⟩. ⟨hal-02533076⟩